enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones

Ron Cooper, Chief Executive Officer of enGene

“As a former urologic oncologist and global clinical development leader, Dr. Goluboff’s industry experience and clinical perspective are uniquely suited to support our detalimogene BLA filing and commercialization plans.”

Ron Cooper, Chief Executive Officer of enGene

“At the same time, Jason Duncan brings to us a rare combination of legal, governance and operational experience helping scale biotechnology companies through late-stage development, regulatory approvals, and commercialization.”

Ron Cooper, Chief Executive Officer of enGene

“We would like to thank Dr. Bill Grossman, a member of our Board of Directors, for his contributions and support while serving as interim Chief Medical Officer since June of this year.”

Erik T. Goluboff, Chief Medical Officer of enGene

“The emerging detalimogene profile may provide busy urology practices with a unique balance of efficacy and tolerability without disruption to standard clinical workflows.”

Erik T. Goluboff, Chief Medical Officer of enGene

“I am excited about being part of an important BLA submission and the potential to bring a new bladder-sparing treatment option to patients.”

Jason Duncan, Chief Legal and Administrative Officer of enGene

“With a planned BLA filing later this quarter and preparations for a potential approval of detalimogene next year, I am thrilled to join enGene at this transitional time.”